A groundbreaking new medication for type 2 diabetes has the potential to save thousands of lives each year, according to a recent study. Researchers have hailed the once-daily SGLT-2 inhibitor tablets as an effective treatment for a diverse array of patients, following endorsement from the National Institute for Health and Care Excellence (NICE). This significant shift in diabetes management could lead to a remarkable reduction in premature mortality among those affected by the condition.
A Game-Changer in Diabetes Treatment
The study, conducted by experts at University College London (UCL) and the London School of Hygiene & Tropical Medicine (LSHTM), analysed data from approximately 60,000 individuals across the UK. Findings revealed that patients with type 2 diabetes who were prescribed SGLT-2 inhibitors were 24 per cent less likely to die prematurely over a three-year period compared to those using other blood sugar-lowering treatments.
The SGLT-2 inhibitors, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, function by assisting the kidneys in eliminating glucose from the bloodstream, which is then excreted through urine. This innovative approach not only helps manage blood sugar levels but also offers additional health benefits.
NICE’s Endorsement Signals a New Era
The NICE’s recent endorsement of SGLT-2 inhibitors as a first-line treatment marks a pivotal moment in diabetes care, positioning these medications alongside metformin—the traditional first choice. Dr. David Ryan, a clinical pharmacology expert and PhD student at UCL, emphasised the significance of these findings: “Our study shows this drug works very well in a much wider range of people with type 2 diabetes than we previously had evidence for. Our findings support NICE’s draft guidance proposing its use as a first treatment, which could drastically alter diabetes care for millions.”
With an estimated 4.6 million individuals in the UK living with diabetes, and about 90 per cent of those diagnosed with type 2, the implications of this research are profound. Researchers estimate that around 20,000 lives could be saved each year if SGLT-2 inhibitors are widely adopted.
Addressing Under-Prescription Concerns
In a review of over 590,000 patient records, NICE found that SGLT-2 inhibitors are frequently under-prescribed, particularly among women, older patients, and individuals from Black and minority ethnic backgrounds. The new guidelines recommend that patients unable to tolerate metformin should start treatment with an SGLT-2 inhibitor, which underscores the need for equitable access to these potentially life-saving medications.
Dr. Patrick Bidulka from LSHTM remarked on the importance of leveraging patient data to enhance healthcare outcomes: “This study exemplifies how patient data can inform patient care, demonstrating the value of electronic health records in complementing evidence from randomised controlled trials.”
Why it Matters
The introduction of SGLT-2 inhibitors as a first-line treatment for type 2 diabetes represents a significant advancement in medical practice that could transform the lives of millions. By reducing the risk of premature death and offering additional protective benefits for heart and kidney health, this medication not only addresses the immediate challenges of managing diabetes but also fosters a broader commitment to improving healthcare equity. Ensuring that all patients have access to these innovative treatments could redefine the future of diabetes management and significantly enhance quality of life.
